Cipla's Umang Vohra on Q2 performance and outlook going forward
2019-11-07 162 Dailymotion
Detailing the third quarter performance and outlook going forward Umang Vohra, MD & Global CEO, Cipla said the trade generic segment has recovered and grew 60 percent versus quarter one. The branded Rx prescription business by 13 percent, he said.
Download Instagram Videos
Quickly and easily download Instagram videos with our free tool.